184 related articles for article (PubMed ID: 36387866)
1. The relationship between urinary iodine concentration and papillary thyroid cancer: A systematic review and meta-analysis.
Zhang X; Zhang F; Li Q; Aihaiti R; Feng C; Chen D; Zhao X; Teng W
Front Endocrinol (Lausanne); 2022; 13():1049423. PubMed ID: 36387866
[TBL] [Abstract][Full Text] [Related]
2. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area.
Kim HJ; Park HK; Byun DW; Suh K; Yoo MH; Min YK; Kim SW; Chung JH
Eur J Nutr; 2018 Mar; 57(2):809-815. PubMed ID: 28258306
[TBL] [Abstract][Full Text] [Related]
3. High iodine intake and central lymph node metastasis risk of papillary thyroid cancer.
Zhao H; Li H; Huang T
J Trace Elem Med Biol; 2019 May; 53():16-21. PubMed ID: 30910201
[TBL] [Abstract][Full Text] [Related]
4. Association between Iodine Intake, Thyroid Function, and Papillary Thyroid Cancer: A Case-Control Study.
Kim K; Cho SW; Park YJ; Lee KE; Lee DW; Park SK
Endocrinol Metab (Seoul); 2021 Aug; 36(4):790-799. PubMed ID: 34376043
[TBL] [Abstract][Full Text] [Related]
5. Low urinary iodine is a protective factor of central lymph node metastasis in papillary thyroid cancer: a cross-sectional study.
Zeng Z; Li K; Wang X; Ouyang S; Zhang Z; Liu Z; Sun J; Ye X; Kang W; Yu J
World J Surg Oncol; 2021 Jul; 19(1):208. PubMed ID: 34253203
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.
Ma H; Wang R; Fang J; Zhong Q; Chen X; Hou L; Feng L; Chen X; Huang Z; Zhao H
Medicine (Baltimore); 2020 Jan; 99(5):e18917. PubMed ID: 32000400
[TBL] [Abstract][Full Text] [Related]
7. Iodine nutritional status is not a direct factor in the prevalence of the
Lin YY; Hsieh YS
Arch Endocrinol Metab; 2023 Mar; 67(2):172-178. PubMed ID: 36651704
[TBL] [Abstract][Full Text] [Related]
8. Urinary iodine is increased in papillary thyroid carcinoma but is not altered by regional population iodine intake status: a meta-analysis and implications.
Yan AR; Zhang X; Shen H; Zhou X; Li R; Yuan Z
Endocr J; 2019 Jun; 66(6):497-514. PubMed ID: 30890682
[TBL] [Abstract][Full Text] [Related]
9. High Iodine Nutrition May Be a Risk Factor for Cervical Lymph Node Metastasis in Papillary Thyroid Cancer Patients.
Fan L; Tian Q; Xiu C; Wang F; Yuan Z; He Q; Guo L; Sun Q; Yang X; Miao S; Sun J; Sun D
Ann Nutr Metab; 2021; 77(2):90-99. PubMed ID: 34289482
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Iodine Status among Korean Patients with Papillary Thyroid Cancer Using Dietary and Urinary Iodine.
Choi JY; Lee JH; Song Y
Endocrinol Metab (Seoul); 2021 Jun; 36(3):607-618. PubMed ID: 34154044
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of BRAF
Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
[TBL] [Abstract][Full Text] [Related]
12. Higher urinary bisphenol A concentration and excessive iodine intake are associated with nodular goiter and papillary thyroid carcinoma.
Zhou Z; Zhang J; Jiang F; Xie Y; Zhang X; Jiang L
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28684549
[TBL] [Abstract][Full Text] [Related]
13. High Urinary Iodine, Thyroid Autoantibodies, and Thyroid-Stimulating Hormone for Papillary Thyroid Cancer Risk.
Zhao H; Li H; Huang T
Biol Trace Elem Res; 2018 Aug; 184(2):317-324. PubMed ID: 29164514
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
Li C; Lee KC; Schneider EB; Zeiger MA
J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
[TBL] [Abstract][Full Text] [Related]
15. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
16. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
17. Association between excessive chronic iodine exposure and the occurrence of papillary thyroid carcinoma.
Huang F; Cong W; Xiao J; Zhou Y; Gong M; Sun J; Shan L; Xiao Q; Wang L; Liu J; Yu Z; Jia H
Oncol Lett; 2020 Nov; 20(5):189. PubMed ID: 32952658
[TBL] [Abstract][Full Text] [Related]
18. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.
Guan H; Ji M; Bao R; Yu H; Wang Y; Hou P; Zhang Y; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2009 May; 94(5):1612-7. PubMed ID: 19190105
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
[TBL] [Abstract][Full Text] [Related]
20. Urinary iodine concentration (UIC) could be a promising biomarker for predicting goiter among school-age children: A systematic review and meta-analysis.
Xiu L; Zhong G; Ma X
PLoS One; 2017; 12(3):e0174095. PubMed ID: 28328929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
